Omalizumab treatment for chronic spontaneous urticaria: data from Turkey

Rabia Kara; Bahar Sevimli Dikicier; Mahizer Yaldiz; Busra Koku; Nur Çosansu; Berna Solak

doi:10.5114/ada.2021.109081

eISSN: 2299-0046
ISSN: 1642-395X

Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii

Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

4/2022
vol. 39

Send email

Copy url:

abstract:

Original paper

Omalizumab treatment for chronic spontaneous urticaria: data from Turkey

Rabia Oztas Kara

¹

,

Bahar Sevimli Dikicier

¹

,

Mahizer Yaldiz

¹

,

Busra Koku

¹

,

Nur Cihan Çosansu

¹

,

Berna Solak

¹

Department of Dermatology, Sakarya University Faculty of Medicine, Sakarya, Turkey

Adv Dermatol Allergol 2022; XXXIX (4): 704-707

DOI: https://doi.org/10.5114/ada.2021.109081

Online publish date: 2022/09/01

View full text Get citation

Aim
The aim of the study was to investigate data from patients suffering from chronic spontaneous urticaria refractory to conventional therapy, and to document outcomes of omalizumab use.

Material and methods
We conducted a single-centre retrospective study with 175 chronic spontaneous urticaria patients who were treated with 300 mg omalizumab subcutaneously every 4 weeks for at least 6 months. Efficacy, factors affecting outcome, and complications were examined.

Results
The complete response rate was 70.9%. Minor complications were observed in 12% of our patients. Anaphylaxis occurred in 1 patient as a major complication. We did not notice any clinical or laboratory factors predicting response to omalizumab treatment.

Conclusions
The findings show that omalizumab is effective and safe for the treatment of chronic spontaneous urticaria with a dosing of 300 mg/month subcutaneously. However, due to 1 case of anaphylaxis in this small group, we must still remind practitioners to be alert for this possible complication.

keywords:

Omalizumab treatment for chronic spontaneous urticaria: data from Turkey

Rabia Oztas Kara 1 , Bahar Sevimli Dikicier 1 , Mahizer Yaldiz 1 , Busra Koku 1 , Nur Cihan Çosansu 1 , Berna Solak 1

omalizumab, chronic spontaneous, urticaria, treatment

Rabia Oztas Kara

¹

,

Bahar Sevimli Dikicier

¹

,

Mahizer Yaldiz

¹

,

Busra Koku

¹

,

Nur Cihan Çosansu

¹

,

Berna Solak

¹